Skip to main content
SpringerLink
Log in

Sirolimus as primary immunosuppression is effective in attenuating progression of cardiac-allograft vasculopathy

  • Practice Point
  • Published:

From Nature Clinical Practice Cardiovascular Medicine

View current issue Sign up to alerts

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Taylor DO et al. (2007) Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report—2007. J Heart Lung Transplant 26: 769–781

    Article  Google Scholar 

  2. Eisen HJ et al. (2003) Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 349: 847–858

    Article  CAS  Google Scholar 

  3. Stallone G et al. (2005) Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 352: 1317–1323

    Article  CAS  Google Scholar 

  4. Sayegh MH and Remuzzi G (2007) Clinical update: immunosuppression minimisation. Lancet 369: 1676–1678

    Article  Google Scholar 

  5. Hunt J et al (2007) Premature termination of a prospective, open label, randomized, multicenter study of sirolimus to replace calcineurin inhibitors (CNI) in a standard care regimen of CNI, MMF and corticosteroids early after heart transplantation. J Heart Lung Transplant 26 (Suppl 2): 398

    Google Scholar 

Download references

Acknowledgements

The synopsis was written by Rodolfo Medina, Research Editor, Nature Clinical Practice.

Author information

Author notes

  1. Massachusetts General Hospital, Department of Surgery, Cox 654, 55 Fruit Street, Boston, MA 02114, USA madsen@helix.mgh.harvard.edu

Authors and Affiliations

  1. JC Madsen is the Director of the MGH Transplant Center and the W Gerald and Patricia R Austen Distinguished Scholar in Cardiac Surgery at Massachusetts General Hospital, Boston, MA, USA.,

    Joren C Madsen

Authors
  1. Joren C Madsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Madsen, J. Sirolimus as primary immunosuppression is effective in attenuating progression of cardiac-allograft vasculopathy. Nat Rev Cardiol 5, 300–301 (2008). https://doi.org/10.1038/ncpcardio1213

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpcardio1213

  • Springer Nature Limited

Search

Navigation